Perlmutter Cancer Center at NYU Langone | Strategic Alliance Partners

January 07, 2021

In our exclusive interview, Dr. Braunstein and Dr. Richter discuss navigating treatment selection for patients with the newly diagnosed multiple myeloma and the evolving role of minimal residual disease testing.

December 18, 2020

Marc J. Braunstein, MD, PhD, discusses the expanding treatment armamentarium in multiple myeloma.

December 14, 2020

Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of hematologic malignancies.

December 09, 2020

Jeffrey S. Weber, MD, PhD, discusses unmet needs in melanoma.

December 04, 2020

December 4, 2020 — Adjuvant nivolumab demonstrated clinically meaningful improvements in relapse-free survival, overall survival, and distant metastasis-free survival vs placebo in patients with high-risk resected melanoma, even after accounting for disease stage and post-recurrence survival, supporting the use of the anti–PD-1 antibody as a standard adjuvant therapy.

December 01, 2020

Jeffrey S. Weber, MD, PhD, ​deputy director and co-director of the melanoma program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone Health’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses the treatment of lactate dehydrogenase (LDH)​–high melanoma.